Prof Clive Wilson, is the J. P. Todd Professor of Pharmaceutics at Strathclyde University in Glasgow and serves on the European Union Federation of Pharmaceutical Sciences teaching and overseas liaison committee. Major areas of research have been the study of the behaviour of drug formulations in man. He pioneered applications of scintigraphy in the study of physiological and patho-physiological effects on drug absorption following oral, nasal, pulmonary and ophthalmic delivery. In the university, his group collaborates with industry on ophthalmic drug delivery projects especially related to the behaviour of ocular implants. Recent new areas of interest include additive soft and hard matrix technologies for drug delivery, and several programmes in novel therapies for treating ulcerative colitis. Primary Teaching activities are in the field of Biopharmaceutics and formulation research.
Prof. David Jones, is Professor of Biomaterial Science at Queen’s University Belfast and Pro-Vice-Chancellor for Education and Students. His research concerns the characterisation, formulation and engineering of pharmaceutical materials/dosage forms and biomedical devices. He is the author of two textbooks, 6 patents and over 400 research papers/communications and has been awarded the Lilly prize for pharmaceutical research and the British Pharmaceutical Conference Science Award. Professor Jones is both a Chartered Engineer and a Chartered Chemist and is an elected Fellow of the Pharmaceutical Society of Northern Ireland, a Fellow of the Institute of Materials, Minerals and Mining, a Fellow of the Royal Statistical Society, a Member of the Royal Society of Chemistry and a Member of the Institute of Engineers in Ireland. He is the Editor of the Journal of Pharmacy and Pharmacology and is a previous holder of the prestigious position of a Royal Society Industrial Fellow. He has been the founder and Director of two University-based Companies, Xiomateria and Carapacics, both concerned with the design and development of novel medical devices.
Dr Brian Levy, is currently CEO of OcuNexus Therapeutics a Biopharm company developing novel and differentiated products in ophthalmology targeting Gap Junction Channel Modulation. Prior to OcuNexus he was Chief Medical Officer at Aerie Pharmaceuticals developing Rho Kinase Inhibitors for the lowering of IOP in patients with Glaucoma and prior to that Chief Operating Officer at Danube Pharmaceuticals a startup also developing a product for lowering of IOP. Before entering the startup world he was Corporate Vice President R&D and Chief Medical Officer at Bausch & Lomb for 15 years. At Bausch & Lomb he was responsible for 3 NDA’s for pharmaceuticals (Retisert, Zylet, Besivance) all FDA approved and currently in the market. Prior to Bausch & Lomb he was Associate Professor, Department of Ophthalmology at California Pacific Medical Center in San Francisco and prior to that in private practice in Toronto and a clinical investigator and consultant to the ophthalmic industry. He received a Doctor of Optometry degree from the University of California at Berkeley and a Master of Science in comparative anatomy and physiology of the eye at University of Waterloo in Canada.
Dr. Kuppermann is the Roger F. Steinert Professor, Chair of the Department of Ophthalmology, and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the Department of Biomedical Engineering at UC Irvine.
After earning his PhD in neuroscience at the California Institute of Technology and his medical degree at the University of Miami in Florida, Dr. Kuppermann completed his internship at the Los Angeles County/University of Southern California Medical Center and his residency in ophthalmology at the University of Southern California Doheny Eye Institute in Los Angeles. In addition, he completed fellowships in retina and vitreous at St. Joseph Medical Center in Baltimore, Maryland and at the University of California, San Diego.
His laboratory research focuses on assessing the toxicity of drugs on retinal cells in culture, including various vital stains, steroids, and anti-VEGF compounds. More recently, the lab has modified its focus to study the effect of mitochondrial genetics on retinal diseases such as age-related macular degeneration and diabetic macular edema. He is also active in the development of drug delivery systems for the posterior segment through collaborative work with the Department of Biomedical Engineering at UC Irvine. Dr. Kuppermann has published extensively in the peer-reviewed literature, has been a visiting professor at a number of universities in the United States and Europe, and has given several named lectureships. He is also extensively involved in clinical research, having served as Principal Investigator in many trials evaluating new drugs and technologies for the treatment of age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
Dr. Kuppermann is listed as one of the best doctors in America, as well as one of the “Best Ophthalmologists in Orange County” by Orange Coast Magazine.